The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

BioAge Labs (NASDAQ: BIOA) emerged as a standout performer in the weight-loss drug sector last week, with its stock skyrocketing 46.6% in the week ending October 25. The rally was primarily ...

More work needs to be done to tease out the mechanisms by which GLP-1 RAs lower the risk of MACE, researchers say.

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

The EMA is working with social media content creators to try to encourage "safe and responsible" use of weight-loss drugs.

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.